



¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/506,893
				Nat. Phase Filing Date	09/07/2004
				First Named Inventor	Eming
				Group Art Unit	NA 1647
				Examiner Name	NA Saoud
Sheet	2	of	3	Attorney Docket Number	3030-101
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
/C.S./	1	FRANK, S. ET AL, "Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes IMPLICATIONS FOR NORMAL AND IMPAIRED WOUND HEALING", JBC Online, Vol. 270, No. 21: 12607-12613 (May 26, 1995).			
	2	FUKUMURA, D. ET AL, "Tumor Induction of VEGF Promoter Activity in Stromal Cells", Cell, Vol. 94: 715-725 (September 18, 1998).			
	3	GOSPODAROWICZ, D. ET AL, "Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells", Proc. Natl. Acad. Sci. USA, Vol. 86: 7311-7315 (October 1989).			
	4	KECK, P. ET AL, "Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF", Science, Vol. 246: 1309-1312 (December 8, 1989).			
	5	+KEYT, B. ET AL, "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency", The Journal of Biological Chemistry, Vol. 271, No. 13: 7788-7795 (March 29, 1996).			
	6	+LAUER, G. ET AL, "Expression and Proteolysis of Vascular Endothelial Growth Factor is Increased in Chronic Wounds", The Journal of Investigative Dermatology, Vol. 115, No. 1: 12-18 (July 2000).			
	7	*LAUER, G. ET AL, "Expression of the soluble variant of the vascular endothelial growth factor receptor Flt-1 in chronic wounds", Wound Repair and Regeneration, Vo. 8, No. 5 (September 2000).			
	8	*LAUER, G. ET AL, "Generation of a novel proteolysis resistant vascular endothelial growth factor 165 variant by a site-directed mutation at the plasmin sensitive cleavage site", FEBS Lett., 531(2):309-13 (Nov. 6, 2002).			
	9	*LAUER, G. ET AL, "VEGF expression chronic non-healing wounds", Archives of Dermatological Research, Vol. 293, No. 1-2, P145, page 79 (February 2001).			
	10	LAWRENCE, W. ET AL, "Growth Factors in Wound Healing", Clinics in Dermatology, 12: 157-169 (1994).			
	11	*MARKET, Y. ET AL, "Increased proteolytic resistance of ribonuclease A by protein engineering", Protein Engineering, England, Vol. 14, No. 10 (October 2001).			
	12	MOHANRAJ, D. ET AL, "Expression of Biologically Active Human Vascular Endothelial Growth Factor in Yeast", Growth Factors, Vol. 12: 17-27 (1995).			
/C.S./	13	+NISSEN, N. ET AL, "Vascular Endothelial Growth Factor Mediates Angiogenic Activity during the Proliferative Phase of Wound Healing", American Journal of Pathology, Vol. 152, No. 6: 1445-1452 (June 1998).			
Examiner Signature	/Christine Saoud/			Date Considered	06/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/506,893
				Nat. Phase Filing Date	09/07/2004
				First Named Inventor	Eming
				Group Art Unit	NA 1647
				Examiner Name	NA Saoud
Sheet	3	of	3	Attorney Docket Number	3030-101
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
/C.S./	14	POWERS, J.C. ET AL, "Proteases-structures, mechanism and inhibitors", NCBI abstract of Agents Actions Suppl., 42: 3-18 (1993) (Abstract).			
	15	*Robinson, C. J. ET AL, "The splice variants of vascular endothelial growth factor (VEGF) and their receptors", Journal of cell Science, England, Vo. 114, No. Pt 5 (March 2001).			
	16	SCHARFFETTER-KOCHANKE, K. ET AL, "Chronische Wunden und Wachstumsfaktoren Chronic wounds and growth factors", Zeitschrift für Hautkrankheiten, H&G, 11 (74): 664-672 (1999).			AB
	17	SOKER, S. ET AL, "Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor", Cell, Vol. 92: 735-745 (March 20, 1998).			
/C.S./	18	*WU, X.C. ET AL, "Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life", Appl Environ Microbiol., 64(3):824-9 (March 1998).			
Examiner Signature	/Christine Saoud/			Date Considered	06/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

BEST AVAILABLE COPY

HVP#LLP#CC##

3016571283

p. 7

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the Japanese fiscal year.

*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

BEST AVAILABLE COPY

Dec 01 2005 8:34PM

HVP#LLP#CC##

3016571283

P. 8

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>		
				Application Number	10/506,893	
				Nat. Phase Filing Date	09/07/2004	
				First Named Inventor	Eming	
				Group Art Unit	NA 1647	
				Examiner Name	NA Saoud	
Sheet	2	of	2	Attorney Docket Number	3030-101	
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
/C.S./	14	POWERS, J.C. ET AL, "Proteases-structures, mechanism and inhibitors", in <i>PROTEASES, PROTEASE INHIBITORS AND PROTEASE DERIVED PEPTIDES</i> , Agents Actions Suppl., 42: 3-18 (Publ. Birkhaeuser, 1993).				
Examiner Signature	/Christine Saoud/				Date Considered	06/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Complete if Known

10/506,893

09/07/2004

Eming

NA

NA

1

3

3030-101

U.S. Patent Document

Cite
No. 1Kind Code²
(if known)

Date of Publication
of Cited Document
MM-DD-YYYY

Foreign Patent Document

Cite
No.¹Kind⁵
(if known)

Date of Publication of
Cited Document
MM-DD-YYYY

Date
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/506,893
Nat. Phase Filing Date 09/07/2004
First Named Inventor Eming
Group Art Unit NA
Examiner Name NA

Sheet 2 of 3 Attorney Docket Number 3030-101

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	FRANK, S. ET AL, "Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes IMPLICATIONS FOR NORMAL AND IMPAIRED WOUND HEALING", JBC Online, Vol. 270, No. 21: 12607-12613 (May 26, 1995).	
	2	FUKUMURA, D. ET AL, "Tumor Induction of VEGF Promoter Activity in Stromal Cells", Cell, Vol. 94: 715-725 (September 18, 1998).	
	3	GOSPODAROWICZ, D. ET AL, "Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells", Proc. Natl. Acad. Sci. USA, Vol. 86: 7311-7315 (October 1989).	
	4	KECK, P. ET AL, "Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF", Science, Vol. 246: 1309-1312 (December 8, 1989).	
	5	+KEYT, B. ET AL, "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency", The Journal of Biological Chemistry, Vol. 271, No. 13: 7788-7795 (March 29, 1996).	
	6	+LAUER, G. ET AL, "Expression and Proteolysis of Vascular Endothelial Growth Factor is Increased in Chronic Wounds", The Journal of Investigative Dermatology, Vol. 115, No. 1: 12-18 (July 2000).	
	7	*LAUER, G. ET AL, "Expression of the soluble variant of the vascular endothelial growth factor receptor Flt-1 in chronic wounds", Wound Repair and Regeneration, Vo. 8, No. 5 (September 2000).	
	8	*LAUER, G. ET AL, "Generation of a novel proteolysis resistant vascular endothelial growth factor 165 variant by a site-directed mutation at the plasmin sensitive cleavage site", FEBS Lett., 531(2):309-313 (Nov. 6, 2002).	
	9	*LAUER, G. ET AL, "VEGF expression chronic non-healing wounds", Archives of Dermatological Research, Vol. 293, No. 1-2, P145, page 79 (February 2001).	
	10	LAWRENCE, W. ET AL, "Growth Factors in Wound Healing", Clinics in Dermatology, 12: 157-165 (1994).	
	11	*MARKET, Y. ET AL, "Increased proteolytic resistance of ribonuclease A by protein engineering", Protein Engineering, England, Vol. 14, No. 10 (October 2001).	
	12	MOHANRAJ, D. ET AL, "Expression of Biologically Active Human Vascular Endothelial Growth Factor in Yeast", Growth Factors, Vol. 12: 17-27 (1995).	
	13	+NISSEN, N. ET AL, "Vascular Endothelial Growth Factor Mediates Angiogenic Activity during the Proliferative Phase of Wound Healing", American Journal of Pathology, Vol. 152, No. 6: 1445-1452 (June 1998).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/506,893
Nat. Phase Filing Date	09/07/2004
First Named Inventor	Eming
Group Art Unit	NA
Examiner Name	NA

Sheet	3	of	3	Attorney Docket Number	3030-101
-------	---	----	---	------------------------	----------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	14	POWERS, J.C. ET AL, "Proteases-structures, mechanism and inhibitors", NCBI abstract of Agents Actions Suppl., 42: 3-18 (1993) (Abstract).	
	15	*Robinson, C. J. ET AL, "The splice variants of vascular endothelial growth factor (VEGF) and their receptors", Journal of cell Science, England, Vo. 114, No. Pt 5 (March 2001).	
	16	SCHARFFETTER-KOCHANKE, K. ET AL, "Chronische Wunden und Wachstumsfaktoren Chronic wounds and growth factors", Zeitschrift für Hautkrankheiten, H&G, 11 (74): 664-672 (1999).	AB
	17	SOKER, S. ET AL, "Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor", Cell, Vol. 92: 735-745 (March 20, 1998).	
	18	*WU, X.C. ET AL, "Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life", Appl Environ Microbiol., 64(3):824-9 (March 1998).	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.